Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

Our plain-English summary of Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms, by D.J. Morré, B. Hostetler, D.J. Taggart, et al (Clinical Proteomics, 2016).

The study

• Authors: D.J. Morré, B. Hostetler, D.J. Taggart, D.M. Morré, A.W. Musk, B.W. Robinson, J. Creaney
• Journal: Clinical Proteomics
• Published: 2016;13:3
• Read it: PubMed · Publisher · Free full text

Abstract

[This corrects the article doi:10.1186/s12014-016-9103-3.].

In plain English

This document is an erratum, a published correction, and not a research report. It states that the original version of the article "ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms" (Clinical Proteomics 2016;13:2) contained an unnecessarily complicated version of the data in Table 1, and it replaces that table. The erratum itself reports no findings on early detection, on asbestos exposure, or on the 4 to 10 year time frame named in the title. The replacement table gives ranges of molecular weight and isoelectric point (99th percentile) for ENOX2 transcript variants. It covers 16 common cancer types compared with mesothelioma, 1520 cases in total. Data for the other cancers came from unpublished records in the ONCOblot Tissue of Origin Database of MorNuCo, Inc. The mesothelioma row, 18 cases from the original study, lists two ranges: 60 to 68 kDa with isoelectric point 3.8 to 4.1, and 38 to 44 kDa with isoelectric point 3.8 to 4.6. The erratum states no conclusions or limitations.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Erratum (published correction) replacing Table 1 of an earlier article
• Who was studied: Replacement Table 1 lists 16 common cancer types plus mesothelioma, 1520 cases in total. There are 18 mesothelioma cases from the original study. Data for the other cancers are unpublished data from the ONCOblot Tissue of Origin Database, MorNuCo, Inc.
• Main results:
  • The original article's Table 1 contained an unnecessarily complicated version of the data and is replaced by the table in this erratum.
  • For mesothelioma (18 cases, from the original study), the table lists two ENOX2 ranges: molecular weight 60 to 68 kDa with isoelectric point 3.8 to 4.1, and molecular weight 38 to 44 kDa with isoelectric point 3.8 to 4.6.
  • The table covers a total of 1520 cases across all cancer types listed.

Topics

Medical terms in this study, explained in our Lexicon: Malignant Mesothelioma.

Related studies

• ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms — D.J. Morré, B. Hostetler, et al. (2016)
• Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma — J. Creaney, N.J. Olsen, et al. (2010)
• Biphasic lung diffusing capacity: detection of early asbestos induced changes in lung function — Z. Dujić, J. Tocilj, et al. (1992)
• Recent advances in the early diagnosis of asbestosis — R. Bégin, G. Ostiguy, et al. (1992)
• A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial — S. Gunatilake, F.J. Brims, et al. (2014)
• Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications — B. Tolani, L.A. Acevedo, et al. (2018)

Browse return to medical research.